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Abstract 
 Treatment of rats with monocrotaline (MCT), a pyrrolizidine alkaloid plant 
toxin, is known to cause pulmonary hypertension (PH), and it has been used as a useful 
experimental model of PH. Recent findings suggested that pulmonary inflammation 
may play a significant role in the pathogenesis of MCT-induced PH. We also 
demonstrated that, following MCT administration to rats, there was a significant and 
sustained increase in the pulmonary expression of heme oxygenase-1 (HO-1), which is 
known to be induced by various oxidative stresses, including inflammation and free 
heme, and is thought to be essential in the protection against oxidative tissue injuries. In 
this study, we administered hemin (ferriprotoporphyrin chloride, 30 μmol/kg b.w., 
subcutaneously), a potent inducer of HO-1, every 3 days to rats following subcutaneous 
administration of MCT (60 mg/kg) and examined its effect on MCT-induced PH and 
pulmonary inflammation. MCT administration caused pulmonary arterial wall 
thickening with marked elevation of right ventricular pressure, in association with 
prominent pulmonary inflammation as revealed by the increase in gene expression of 
tumor necrosis factor-α and the number of infiltrated neutrophils in the lung. In contrast, 
hemin treatment of MCT-administered animals, which led to a further increase in 
pulmonary HO-1 mRNA expression, significantly ameliorated MCT-induced PH as well 
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as tissue inflammation. These findings suggest that hemin treatment ameliorates 
MCT-induced PH possibly mediated through induction of pulmonary HO-1 which leads 
to the attenuation of pulmonary inflammation. 
 
Key words:  heme oxygenase-1, hemin, inflammation. monocrotaline, pulmonary 
hypertension, tumor necrosis factor-α  
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Introduction 
Pulmonary hypertension (PH) is a serious and progressive disorder with poor 
prognosis [1, 2]. The pathophysiology of PH remains elusive, but recent findings 
suggest that oxidative stress due to pulmonary inflammation [3, 4] may be involved in 
its pathogenesis [5, 6]. Treatment of animals with monocrotaline (MCT), a pyrrolizidine 
alkaloid, causes significant pulmonary inflammation and cardiac hypertrophy, 
ultimately developing PH, and is used as an experimental model of PH [4]. Heme 
oxygenase-1 (HO-1), the rate-limiting enzyme in heme catabolism, is induced not only 
by its substrate heme but also by oxidative stress [7-10]. HO-1 has been considered to 
confer protection against tissue injuries due to various stimuli, including oxidative stress 
[7-10]. Our previous findings suggested that HO-1 may play a significant role in the 
protection of lung tissue injuries caused by MCT treatment [11]. With this point in mind, 
we examined in the present study the effect of administration of hemin, an oxidized 
form of heme that is available as a chemical, to MCT-treated rats. We report here that 
hemin treatment significantly ameliorated MCT-induced PH, together with the 
attenuation of pulmonary inflammation. Our findings also demonstrated that treatment 
of MCT animals with hemin further increased gene expression of HO-1 than that caused 
by MCT treatment alone. These findings suggest that hemin treatment ameliorates 
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MCT-induced PH by induction of HO-1 which may contributes to the attenuation of 
pulmonary inflammation. 
 
Results 
Effect of hemin treatment on MCT-induced PH and lung histology 
 We administered hemin to MCT-treated rats and examined its effect on RV 
pressure and lung morphology. At 3 weeks after MCT treatment, RV pressure in animals 
significantly increased compared with that in untreated control animals (P<0.05) (Fig. 
(1)) [11]. Its level was ∼2.5 times greater than that of control animals. In contrast, hemin 
treatment of MCT animals resulted in a marked decrease in RV pressure (P<0.05, vs. 
Vehicle-treated MCT animals) that was essentially similar to that of untreated control 
animals (Fig. (1)). MCT-treated animals showed extensive infiltration of inflammatory 
cells in the lung interstitium and thickening of pulmonary arterial walls at 3 weeks after 
MCT treatment, while sections of the lung from control animals were essentially normal 
(Fig. (2)) [11]. Hemin-treated MCT animals showed markedly lesser infiltration of 
inflammatory cells and reduction of wall thickness of pulmonary arteries, compared 
with MCT treatment alone. These results indicate that hemin treatment significantly 
ameliorated MCT-induced PH as well as the infiltration of inflammatory cells. 
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Effect of hemin treatment on pulmonary inflammation 
 Next, we examined the extent of pulmonary inflammation by assessing gene 
expression of tumor necrosis factor (TNF)-α and the number of infiltrating neutrophils 
into the lung. While pulmonary TNF-α mRNA was hardly detectable in untreated 
control rats, the level in MCT-treated animals was markedly increased at 2 weeks after 
the treatment (P<0.05, vs. untreated control animals) (Fig. (3A)) [11]. In contrast, the 
level in the hemin-treated MCT animals was markedly decreased (P<0.05, vs. 
Vehicle-treated MCT animals) and reached almost the same level as in the untreated 
control animals (Fig. (3A)). Consistent with changes in TNF-α gene expression, the 
number of infiltrating neutrophils markedly increased in MCT-treated animals compared 
with that in the untreated control animals (P<0.05) (Fig. (4)). Neutrophils were 
homogenously distributed in the lung interstitium of MCT-treated animals. In contrast, 
neutrophil recruitment was markedly reduced in the lung of hemin-treated MCT animals, 
and the number was significantly decreased (P<0.05, vs. Vehicle-treated MCT animals) 
(Fig. (4)). These findings thus indicate that hemin treatment attenuates MCT-induced 
inflammatory changes, including suppression of neutrophil recruitment.  
Effect of hemin treatment on HO-1 gene expression 
Since hemin is known as a potent inducer of HO-1 in various types of cells [12] 
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including pulmonary cells [13], we examined the effect of hemin treatment on the 
expression of HO-1 mRNA in the lung. HO-1 mRNA was barely detectable in the lungs 
of untreated-treated control animals (Fig. (3B)). However, HO-1 mRNA level was 
significantly increased in the lungs of MCT-treated animals at 2 weeks after the 
treatment (P<0.05 vs. untreated control animals) (Fig. (3B)). Hemin administration to 
MCT-treated animals resulted in a further increase in HO-1 mRNA level at 2 weeks 
after MCT treatment (P<0.05, vs. Vehicle-treated MCT animals). The level of HO-1 
mRNA in the lungs of hemin-treated MCT animals was approximately 5-fold greater 
than that of MCT-treated animals. These results indicate that hemin treatment 
significantly augmented the MCT-induced level of HO-1 mRNA. 
 
Discussion 
 The present study demonstrated that hemin treatment markedly ameliorated 
MCT-induced PH. Hemin treatment also significantly attenuated MCT-induced 
pulmonary inflammation. Our findings also showed that, while MCT treatment alone 
caused a substantial increase (∼20-fold) in HO-1 mRNA, hemin treatment further 
increased its level by 5-fold. These results suggest that amelioration of MCT-induced 
PH by hemin treatment is possibly mediated by its potent ability to induce HO-1. Since 
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certain synthetic heme analogues has been shown to possess the ability to 
simultaneously inhibit as well as induce the enzyme HO [14], the effect of hemin 
administration on HO activity in MCT-treated animals should be clarified in future 
study. 
 MCT administration caused severe PH as confirmed by a marked increase in 
RV pressure. In contrast, hemin administration to MCT-treated animals markedly 
suppressed the MCT-mediated increase in RV pressure (Fig. (1)). In addition, lung 
sections of hemin-treated MCT animals showed a significant reduction of wall thickness 
of the pulmonary artery compared with that in MCT-treated animals (Fig. (2)). Thus, 
these findings clearly indicated that hemin treatment can abrogate the development of 
PH induced by MCT.  
 Our study also demonstrated that hemin administration to MCT-treated animals 
resulted in a significantly lower TNF-α mRNA level compared with that in 
hemin-untreated control animals (Fig. (3A)). Furthermore, histological examination 
revealed that hemin treatment markedly decreased the infiltration of inflammatory cells 
and reduced the recruitment of neutrophils to the lung in MCT animals (Figs. (2) & (4)), 
suggesting that hemin treatment attenuates MCT-induced PH by suppressing pulmonary 
inflammatory cell infiltration [4]. It has been reported that inhibition of inflammation by 
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interleukin-1 receptor antagonists, or by an antibody that neutralizes monocyte 
chemotactic and activating factor/monocyte chemoattractant protein-1 alleviates 
MCT-induced pulmonary hypertension [15, 16]. Very recently, interleukin-10, 
anti-inflammatory cytokine, has also been reported to prevent the development of a rat 
model of MCT-induced PH [17]. Thus, in addition to the hemin-mediated protection, 
these mechanisms may constitute an additional mechanism in the protection against 
MCH-induced PH.  It is unclear at present whether hemin treatment may involve these 
immunological modulations in its protective mechanism, but the question clearly 
remains as an important one for a future study.   
 The mechanism behind the anti-inflammatory effect of hemin may thus remain 
somewhat elusive. However, our results clearly demonstrated that administration of 
hemin to MCT-treated animals further increased the MCT-induced level of pulmonary 
HO-1 mRNA (Fig. (3B)). There are abundant evidence in various models that HO-1 has 
a potent anti-inflammatory and anti-oxidative property in various tissues and organs 
[7-10]. For instances, overexpression of human HO-1 has been shown to attenuate 
TNF-α-mediated inflammation injury in endothelial cells [18]. Moreover, very recently, 
it has been reported that hemin pretreatment induced a significant decrease in oxidative 
stress and TNF-α plasma levels with a significant increase of interleukin-10 plasma 
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levels via HO-1 induction in lipopolysaccharide-treated rats [19]. Thus, hemin-mediated 
induction of HO-1 in the MCT-PH model constitutes another example of the potent 
anti-inflammatory and anti-oxidative property of HO-1 induction in the lung. In line 
with this conclusion, it has been reported that inhibition of HO activity by 
tin-protoporphyrin potentiated inflammatory changes in the lung and resultant RV 
hypertrophy in the MCT-induced PH model [20]. Very recently, rapamycin, an 
immunosuppressive agent, has been shown to ameliorate MCT-induced PH via HO-1 
induction in rats [21]. In addition, a low dose of inhalation of CO, which is a 
physiological product of the HO reaction, reversed the established MCT-induced PH 
[22].  
 In summary, our study demonstrated that hemin treatment after MCT 
administration abrogated the development of PH induced by MCT, which is at least in 
part mediated by its potent induction of HO-1. Our findings also indicate that HO-1 
induced by hemin treatment might serve as an important protective measure, and hemin 
may be a novel target for modulating the development of PH, although further studies to 
elucidate the dose-dependent effect of hemin on PH and to analyze the mechanism(s) 
behind the anti-inflammatory effect of hemin are clearly needed. 
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Experimental Section 
Animals and treatments 
The studies reported herein conform to guidelines for the care and use of 
laboratory animals established by Animal Use and Care Committee of the Okayama 
University Medical School. Male Sprague-Dawley rats weighing 150-200 g were 
purchased from Charles River (Yokohama, Japan). They were housed in a 
temperature-controlled (25°C) room with alternating 12 h/12 h light/dark cycles and 
were allowed free access to water and chow diet until the start of experiments. 
PH was induced by MCT treatment as described previously [11]. Animals were injected 
subcutaneously with MCT (Sigma Chemical Co., St. Louis, MO; 60 mg/kg body weight 
(b.w.)) which was dissolved in 0.1N HCl and then pH was adjusted to 7.4 with 0.1N 
NaOH. The final concentration was a 2% MCT solution (w/v). Control rats received the 
same volume of physiological saline. After the injection, animals were returned to cages 
and allowed free access to food and water. MCT animals were divided into the 
following two groups: treatment with hemin (ferriprotoporphyrin chloride, 30 μmol/kg 
b.w., subcutaneously) every 3 days after MCT treatment and treatment with the same 
volume of physiological saline every 3 days after MCT treatment. Hemin was dissolved 
in an alkaline solution (0.1N NaOH), and then reconstituted in physiological saline [23]. 
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We previously reported that treatment of hemin with this dose significantly increased 
hepatic HO activity in rats without any adverse effect [23]. Under light anesthesia with 
ethyl ether, animals were sacrificed by decapitation at each defined time point (0 to 3 
weeks). Lungs were excised and frozen immediately in liquid nitrogen and stored at 
-80°C until use for the preparation of RNA.  
Measurement of RV pressure 
 RV pressure was measured as described previously [11]. Briefly, animals were 
anesthetized with intraperitoneal injection of sodium pentobarbital (20 mg/kg b.w.), 
intubated with a 16 G tube by tracheostomy, and ventilated with a rodent ventilator 
(SN-480-7TM, Shinao Manufacturing Co. Ltd., Tokyo, Japan). An incision was made in 
the right side of the animal's neck, and dissection was performed to expose the right 
jugular vein. A curve tipped 22 G catheter (Arrow International Inc., Reading, PA) was 
inserted into the vein and advanced into the RV. The catheter was connected to the 
pressure transducer linked to a polygraph system (RM-6000™, Nihon Kohden Corp. 
Tokyo, Japan), and RV systolic pressure was measured. 
RNA isolation and Northern blot analysis  
Total RNA was isolated from rat tissues using Tri-ReagentTM (Sigma Chemical 
Co.) according to the manufacturer’s protocol. Northern blotting was performed as 
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described previously [11, 24]. Twenty micrograms of total RNA were subjected to 
electrophoresis in a 1.2% (w/v) agarose gel containing 6.5% (v/v) formaldehyde. After 
blotting on to a sheet of BIO-RAD Zeta-ProbeTM membrane (Bio-Rad Laboratories, 
Richmond, CA), RNA samples were hybridized with [α-32P] dCTP labeled cDNA 
probes for HO-1 [25] and TNF-α [26, 27], respectively, followed by washing under 
stringent conditions. The membrane was exposed to a sheet of Fuji Medical radiograph 
film with an intensifying screen at -70°C, and autoradiographs and 18S ribosomal RNA 
were quantified by using an image scanner (GelPrintTM 2000i, Genomic Solutions, Ann 
Arbor, MI) and a computerized image analysis software (Basic QuantifierTM version 3.0, 
Genomic Solutions). Relative amounts of radiolabelled cDNA that hybridized to the 
blots were normalized to 18S ribosomal RNA levels for loading errors.  
Histological study 
For histological examination, lung tissue was fixed in 10% neutral buffered 
formalin, embedded in paraffin, and sectioned at 4-6 μm thickness. After 
deparaffinization and dehydration, sections were stained with hematoxylin and eosin for 
microscopic examination. The neutrophils were stained with the use of a naphthol AS-D 
chloroacetate esterase-staining kit (Sigma Chemical Co.). The number of positively 
stained cells was counted in five non-consecutive sections per rat at a magnification of 
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x400. 
Statistical analysis 
Statistical evaluation was performed with analysis of variance followed by 
Scheffé’s F-test by using Statview software (Abacus Concepts, Berkeley, CA). 
Differences were considered as significant at p < 0.05. Data are presented as means ± 
SEM. 
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Figure legends 
 
Figure 1   Effect of hemin treatment on cardiac right ventricular (RV) pressure 
in monocrotaline (MCT)-induced pulmonary hypertension 
Hemin (30 μmol/kg) or vehicle was administered to rats subcutaneously every 
3 days after MCT treatment (60 mg/kg, s.c.). Control rats received physiological saline. 
RV pressure was measured at 3 weeks after MCT treatment as described in “Materials 
and Methods”. Control, control animals; MCT/Vehicle, MCT with vehicle treatment; 
MCT/hemin, MCT with hemin treatment. RV pressures are shown as mean ± SEM (N = 
6 for each group). Statistical analysis by analysis of variance with Scheffé’s F-test. *p < 
0.05 vs Control; †p < 0.05 vs MCT/Vehicle. 
 
Figure 2   Effect of hemin treatment on histological changes in the lung in 
monocrotaline (MCT)-induced pulmonary hypertension 
 Hemin (30 μmol/kg) or vehicle was administered to rats subcutaneously every 
3 days after MCT treatment (60 mg/kg, s.c.). Control rats received physiological saline. 
Three weeks after MCT treatment, lung sections were stained with hematoxylin and 
eosin. Control, control animals; MCT/Vehicle, MCT with vehicle treatment; MCT/hemin, 
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MCT with hemin treatment. Insets; Pulmonary artery. Representative photomicrograph 
after each treatment from at least three independent experiments. The bar represents 100 
μm.  
 
Figure 3   Effect of hemin treatment on gene expression of tumor necrosis factor 
(TNF)-α and heme oxygenaes-1 (HO-1) in the lung in monocrotaline (MCT) 
-induced pulmonary hypertension 
Hemin (30 μmol/kg) or vehicle was administered to rats subcutaneously every 
3 days after MCT treatment (60 mg/kg, s.c.). Control rats received physiological saline. 
Two weeks after MCT treatment, lungs were removed for Northern blot analysis as 
described in “Materials and Methods”. Control, control animals; MCT/Vehicle, MCT 
with vehicle treatment; MCT/hemin, MCT with hemin treatment.  Top, Shown are the 
autoradiographic signals of RNA blot hybridized with [α-32P]dCTP-labeled TNF-α (A) 
and HO-1 (B) cDNA, respectively. Open and closed arrowheads next to the 
autoradiogram indicated the position of 18S and 28S ribosomal RNA corresponding to 
the ethidium bromide stained gels shown below, respectively. Bottom, The levels of 
TNF-α (A) and HO-1 (B) mRNA are expressed as densitometric arbitrary units. Data 
are expressed mean ± SEM (N = 3 for each group). Statistical analysis by analysis of 
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variance with Scheffé’s F-test. *p < 0.05 vs Control; †p < 0.05 vs MCT/Vehicle. 
 
Figure 4   Effect of hemin treatment on neutrophil infiltration into lung in 
monocrotaline (MCT)-induced pulmonary hypertension 
Hemin (30 μmol/kg) or vehicle was administered to rats subcutaneously every 
3 days after MCT treatment (60 mg/kg, s.c.). Control rats received physiological saline. 
Three weeks after MCT treatment, lung sections were subjected to Naphthol AS-D 
chroloacetate esterase staining. Control, control animals; MCT/Vehicle, MCT with 
vehicle treatment; MCT/hemin, MCT with hemin treatment. Top; Representative 
photomicrograph of six independent experiments. Arrows indicate the positively stained 
cells. The bar represents 100 μm. Bottom; The number of neutrophils in five 
non-consecutive sections per rat at a magnification of x400. Data are expressed as mean 
± SEM (N=6 for each group). Statistical analysis by analysis of variance with Scheffé’s 
F-test. *p < 0.05 vs Control; †p < 0.05 vs MCT/Vehicle. 
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